Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

SEATTLE, Dec. 05, 2023 -- Adaptive Biotechnologies Corporation , a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to...

Related Keywords

Seattle ,Washington ,United States ,San Diego ,California ,Wisconsin ,American ,Karina Calzadilla ,Susan Bobulsky ,Erica Jones ,Idecabtagene Vicleucel ,Elranatamab Monotherapy ,Lenalidomide Vi ,Daratumumab Krd ,Obinutuzumab Clb ,Cellectis Biologics ,Lisocabtagene Maraleucel ,A Wisconsin Oncology Network Study ,Adaptive Biotechnologies Corporation Nasdaq ,Meeting Of The American Society Hematology ,Drug Administration ,Exchange Commission ,Corporate Communications ,Biotechnologies Corporation ,Annual Meeting ,American Society ,Senior Vice President ,Versus Vrd Alone ,Newly Diagnosed Multiple Myeloma ,Who Are Eligible ,Autologous Stem Cell Transplantation ,Primary Results ,Month Median Follow Up ,Line Fixed Duration Ibrutinib Plus Venetoclax ,Versus Chlorambucil Plus Obinutuzumab ,Month Follow Up ,Multi Targeted Therapy ,Diffuse Largeb Cell Lymphoma ,Multicenter Phase ,Mutant Mantle Cell ,Refractory Mantle Cell ,Newly Diagnosed Fit ,Sustained Undetectable Minimal Residual Disease ,Dexamethasone Elicits Deep ,Durable Responses ,Refractory Multiple Myeloma ,Updated Analyses ,Minimal Residual Disease Negativity ,Versus Standard ,Updated Analysis ,Next Generation Sequencing ,Identify Trackable Clonotypic Sequences ,Minimal Residual Disease Testing ,B Cell Acute Lymphoblastic Leukemia ,Venetoclax Based Regimens ,Stable Disease ,Lisocabtagene Maraleucel Treatment ,Exploratory Analysis ,Duration Pirtobrutinib Combined ,Refractory Chronic Lymphocytic Leukemia ,Updated Results ,Sequence Uniqueness ,Refractory Follicular Lymphoma ,First Data Disclosure ,Lymphoma Dose Expansion ,Residual Disease ,Status Predicts Outcomes ,Follicular Lymphoma ,Mantle Cell Lymphoma Enables Early Relapse ,Rituximab As First Line Therapy ,Older Patients ,Mantle Cell Lymphoma ,Testing By Next Generation Sequencing ,Two Cycles ,Remission Duration ,Maintenance Therapy ,Previously Untreated Mantle Cell Lymphoma ,Wisconsin Oncology Network ,Receiving Elotuzumab ,Inadequate Response ,Frontline Autologous Stem Cell Transplantation ,Multiple Myeloma ,Clone Size ,Assessed By Next Generation Sequencing ,Receiving Modern ,Induces Favorable Responses ,Endpoint Analysis ,Response Adaptive Phase ,Dexamethasone Plus Daratumumab ,Term Efficacy ,T Cell Engagement ,Cevostamab Consolidation Following ,Once Weekly Carfilzomib ,Newly Diagnosed ,Transplant Eligible Multiple Myeloma ,Minimal Residual Disease ,Post Transplant Treatment ,Versus Lenalidomide ,High Risk Smoldering Multiple ,Real World Observational Study Using ,Adaptive Biotechnologie ,Financial Condition ,Vice President ,Associate Director ,Markets ,